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LETTER TO THE EDITOR
Reply to the letter from Dr Colls
Sir - The data on secondary leukaemia following etoposide
chemotherapy are still far from clear. It seems to be
associated particularly with high doses in children and has a
short latency (2-3 years). Two recently published large
studies incorporating etoposide in Hodgkin's disease over a
10 year period report no cases of leukaemia so far (Hancock
et al., 1992; Cullen et al., 1994). This includes our own
Central Lymphoma Group study in which etoposide is com-
bined with bleomycin (Cullen et al., 1994). The MRC
adjuvant chemotherapy study in high-risk stage I non-
seminomatous germ cell tumours of the testis (NSGCTT) will
be published shortly. In 122 patients receiving two courses of
BEP, there have been no cases of leukaemia so far with a
median follow-up of more than 2 years.
At the time of adopting any therapeutic strategy, one must
carefully weigh up efficacy and toxicity. This is no more
important in potentially curative adjuvant therapy than in
potentially curative treatment of more advanced disease.
I suspect one of the reasons Dr Colls and his team swit-
ched from PVB to BEP (although this might have been
forgotten when the above letter was written) was that BEP
was more effective in the definitive trial in advanced disease
as well as having less short-term subjective toxicity (Williams
et al., 1987). Probably at about the same time (1987-88) as
Dr Colls chose BEP for metastatic NSGCTT, the MRC
made the same choice (two courses) for high-risk stage I
disease. The MRC has, for a number of reasons (simplicity,
less alopecia, less myelosuppression, etc.), now chosen vinc-
ristine, bleomycin and cisplatin for high-risk stage I non-
seminoma. It remains to be seen whether it is as effective as
BEP. It also remains to be seen whether Dr Colls will switch
back to PVB on the basis of his own argument.
Yours etc,
M.H. Cullen
Queen Elizabeth Hospital
Edgbaston
Birmingham B15 2TH, UK
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